Common Variable immunodeficiency: predisposing or protective factor for severe complications of COVID-19? (CROSBI ID 316928)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Ferenc, Thomas ; Vilibić-Čavlek, Tatjana
engleski
Common Variable immunodeficiency: predisposing or protective factor for severe complications of COVID-19?
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The usual presentation of the disease is a common cold-like illness but it can present with more severe and sometimes fatal manifestations. Immunocompromised patients such as those with common variable immunodeficiency (CVID) also are among the infected population. A limited number of reports have been published concerning CVID patients with COVID-19. The main reported symptoms were fever, cough, dyspnea and fatigue while the median duration of illness was 19 (interquartile range 14-26.5) days. Total recovery rate was 88.4%. It is still unknown whether primary immunodeficiency interacts as a predisposing or protective factor against the severe forms of COVID-19. Substitute immunoglobulin (IG) therapy is the only treatment option for CVID. Some reports suggest that early administration of intravenous IGs or convalescent plasma infusion may positively influence the outcome of COVID-19 in these patients.
common variable immunodeficiency ; COVID-19 ; SARS-CoV-2
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
61 (1)
2022.
107-113
objavljeno
0353-9466
1333-9451
10.20471/acc.2022.61.01.13
Povezanost rada
Kliničke medicinske znanosti